As the pandemic windfall fades, mRNA vaccine leaders BioNTech (BNTX) and Moderna (MRNA) have both seen their shares struggle, and each now needs to prove the value of its platform beyond COVID-19. Moderna recently grabbed headlines—and a share price surge—after its personalized cancer vaccine, intismeran autogene, delivered strong Phase 3 results. But BioNTech, the other major player digging deep into cancer vaccines, holds a potential game-changer of its own: an investigational drug called pumitamig.
Pumitamig is being developed by BioNTech in collaboration with Bristol Myers Squibb, and some market watchers view it as a possible “Keytruda killer.” Keytruda, from Merck, is the world’s best-selling cancer drug, and pumitamig is being tested across multiple indications in an attempt to challenge that dominance—including lung cancer, the leading cause of cancer death globally. More clinical trial data on pumitamig could arrive within the next 18 months. Positive results could send BioNTech shares soaring.
Beyond pumitamig, BioNTech’s pipeline includes a combined COVID-flu vaccine, an HSV vaccine, and several cancer vaccine candidates. The company did recently suffer a setback when an independent safety review panel recommended halting a Phase 2 trial of autogene cevumeran, an mRNA cancer vaccine targeting colorectal cancer. That news created short-term pressure, but it did not derail the company’s broader cancer vaccine efforts.
On the financial side, BioNTech currently looks modest, with a market capitalization of roughly $26 billion—far below Moderna’s roughly $60 billion. The market is pricing both companies on pipeline progress rather than near-term earnings. Moderna has already delivered strong late-stage data: intismeran autogene combined with Keytruda significantly reduced the risk of recurrence in melanoma patients compared with Keytruda alone. Meanwhile, its influenza vaccine mFLUSIVA has won U.S. regulatory approval and outperformed already-approved flu vaccines in clinical trials, positioning it to add revenue in the coming years.
BioNTech’s late-stage pipeline has not yet produced Phase 3 results of the same caliber, which is the core reason Moderna trades at more than double BioNTech’s valuation. However, if pumitamig delivers a breakthrough in lung cancer or other key areas, that valuation gap could narrow quickly.
From an investment perspective, Moderna offers stronger near-term certainty because of already-achieved clinical milestones. BioNTech, by contrast, behaves more like an option—if the next 18 months bring positive data, the upside could be substantial. For investors watching the cancer vaccine space, these two companies represent contrasting risk-reward profiles: one is a frontrunner nearing commercialization, while the other is a contender waiting for a decisive catalyst.
